News in brief

Imagindairy receives GRAS nod from FDA, acquires industrial-scale precision fermentation lines

By Elizabeth Crawford

- Last updated on GMT

Source: Imagindairy
Source: Imagindairy

Related tags Imagindairy animal free animal free dairy precision fermentation

Israeli-based food-tech startup Imagindairy expects products made with its animal-free dairy protein to launch in the US within the year after it says it received from FDA a letter of no objection for the ingredient’s GRAS status and the subsequent acquisition of an industrial-scale production facility.

The company announced today that it received from FDA last month a “no questions” response letter for the GRAS notice it submitted last summer​ for its animal-free whey protein β-lactoglobulin produced by Aspergillus oryzae strain Ao_st0002 (GRN 1145​).

The tacit greenlight implied in FDA’s response to Imagindairy’s GRAS self-determination means the ingredient can be used at levels ranging rom 5-35% in the US in products ranging from milk and milk-based products, such as yogurt, cheeses, creams and spreads, to dairy-based frozen desserts and mixes to nutritional bars and beverages as well as meal replacements and supplements.

Imagindairy is the third company to receive a hard-to-obtain “no questions letter” from FDA for an animal-free whey protein. Perfect Day previous received a letter of no objection from FDA​ in March 2020 for its animal-free whey made with precision fermentation from a genetically engineered strain of the filamentous fungus Trichoderma reesei, and Remilk, which received a “no questions letter” from FDA last February ​for the production of animal-free whey produced by Komagataella phaffii​ strain “yRMK-66”. 

Imagindairy makes its animal-free dairy through a combination of precision fermentation and a proprietary AI platform, which in combination with its acquisition of its own industrial-scale precision fermentation production lines, announced today, will allow the company to make and sell its animal-free milk proteins at cost parity to traditional dairy, according to the company.

Industrial scale manufacturing will ‘speed up the development of other milk proteins’

The facility gives Imagindairy access to more than 100,000 liters of fermentation capacity that the company says it will dedicate solely to animal-free milk protein production.

With plans to triple production volume in the next one or two years, Imagindairy’s acquisition allows the company to overcome stubborn production capacity limitations that have caused bottlenecks across categories relying on precision fermentation.

Many companies that rely on precision fermentation are using redesigned pharmaceutical facilities, which are not as efficient as they could be – limiting their ability to scale production beyond bench amounts or to a price point that is viable. However, some​ are beginning to build out production capacity.

But Imagindairy claims to already be producing industrial scale batches in its recently acquired facility and at a “competitive cost structure to traditional dairy.”

By enabling companies to bring animal-free dairy products to market at cost parity to traditional dairy, Imagindairy co-founder and CEO Eyal Afergan adds the acquisition “will allow us to support mass-market adoption, transition to an industrial company, and speed up the development of other milk proteins.

Related news

Show more

Related products

show more

Learn more: Future Food-Tech Alternative Proteins

Learn more: Future Food-Tech Alternative Proteins

Content provided by Rethink Events Ltd | 19-Apr-2024 | White Paper

Future Food-Tech Alternative Proteins returns on June 17-18 in a new location for 2024 - the vibrant food and beverage hub, Chicago

How Tech Transforms Pea Protein Production

How Tech Transforms Pea Protein Production

Content provided by Roquette | 13-Nov-2023 | Case Study

Roquette's Canadian pea protein facility is embracing technology-driven changes in production. Key developments include:


Related suppliers

Follow us


View more